Targeting metastatic breast cancer with peptide epitopes derived from autocatalytic loop of Prss14/ST14 membrane serine protease and with monoclonal antibodies

[1]  Seokmann Hong,et al.  B16 melanoma expressing EGFP as a self antigen is differentially immunoedited by tolerogenic thymic epithelial and dendritic cells , 2017 .

[2]  R. Weinberg,et al.  Emerging Biological Principles of Metastasis , 2017, Cell.

[3]  Aparajita Dasgupta,et al.  AECHL-1 targets breast cancer progression via inhibition of metastasis, prevention of EMT and suppression of Cancer Stem Cell characteristics , 2016, Scientific Reports.

[4]  R. Weinberg,et al.  EMT, cell plasticity and metastasis , 2016, Cancer and Metastasis Reviews.

[5]  Chungho Kim,et al.  Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (Prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer , 2016, Oncotarget.

[6]  B. Jena,et al.  Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis. , 2016, American journal of physiology. Cell physiology.

[7]  Li Ma,et al.  The emerging molecular machinery and therapeutic targets of metastasis. , 2015, Trends in pharmacological sciences.

[8]  R. Leduc,et al.  Targeting matriptase in breast cancer abrogates tumor progression via impairment of stromal-epithelial growth factor signaling , 2015, Nature Communications.

[9]  P. Mu,et al.  Targeting Breast Cancer Metastasis , 2015, Breast cancer : basic and clinical research.

[10]  Karina K. Hansen,et al.  Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis , 2014, Oncogene.

[11]  D. Harrison,et al.  Diversity of Matriptase Expression Level and Function in Breast Cancer , 2012, PloS one.

[12]  Christopher Bergum,et al.  Strong expression association between matriptase and its substrate prostasin in breast cancer , 2012, Journal of cellular physiology.

[13]  Dong-Young Kim,et al.  PRSS14/Epithin is induced in macrophages by the IFN-γ/JAK/STAT pathway and mediates transendothelial migration. , 2011, Biochemical and biophysical research communications.

[14]  Alka A. Potdar,et al.  Laminin‐332 cleavage by matriptase alters motility parameters of prostate cancer cells , 2011, The Prostate.

[15]  S. B. Kim,et al.  Epithin/PRSS14 proteolytically regulates angiopoietin receptor Tie2 during transendothelial migration. , 2011, Blood.

[16]  J. Abrams,et al.  A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer. , 2010, Cancer research.

[17]  A. Mannermaa,et al.  ST14 Gene Variant and Decreased Matriptase Protein Expression Predict Poor Breast Cancer Survival , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[18]  S. B. Kim,et al.  Soluble epithin/PRSS14 secreted from cancer cells contains active angiogenic potential , 2010, Molecules and cells.

[19]  S. B. Kim,et al.  Epithin, a target of transforming growth factor-beta signaling, mediates epithelial-mesenchymal transition. , 2010, Biochemical and biophysical research communications.

[20]  Michael D. Johnson,et al.  Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1-mediated inhibition. , 2009, American journal of physiology. Cell physiology.

[21]  M. D'Andrea,et al.  Role of matriptase and proteinase-activated receptor-2 in nonmelanoma skin cancer. , 2009, The Journal of investigative dermatology.

[22]  G. Anderson,et al.  TSCOT + Thymic Epithelial Cell-Mediated Sensitive CD4 Tolerance by Direct Presentation , 2008, PLoS biology.

[23]  Chen-Yong Lin,et al.  The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells. , 2008, Biochimica et biophysica acta.

[24]  J. Segre,et al.  Autosomal Ichthyosis with Hypotrichosis Syndrome Displays Low Matriptase Proteolytic Activity and Is Phenocopied in ST14 Hypomorphic Mice* , 2007, Journal of Biological Chemistry.

[25]  R. Dickson,et al.  Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain. , 2007, American journal of physiology. Cell physiology.

[26]  Bruce H. Hasegawa,et al.  The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans , 2007, Proceedings of the National Academy of Sciences.

[27]  A. Schömig,et al.  Membrane-type serine protease-1/matriptase induces interleukin-6 and -8 in endothelial cells by activation of protease-activated receptor-2: potential implications in atherosclerosis. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[28]  R. Dickson,et al.  Matriptase activates stromelysin (MMP‐3) and promotes tumor growth and angiogenesis , 2006, Cancer science.

[29]  K. Uhland.  Matriptase and its putative role in cancer , 2006, Cellular and Molecular Life Sciences CMLS.

[30]  Ming-Shyue Lee.  Matrix-Degrading Type II Transmembrane Serine Protease Matriptase: Its Role in Cancer Development and Malignancy , 2006 .

[31]  U. Vogel,et al.  The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals , 2006, BMC Cancer.

[32]  B. Nielsen,et al.  Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. , 2005, Genes & development.

[33]  Chen-Yong Lin,et al.  Inhibition of Tumor Invasion by Genomic Down-regulation of Matriptase through Suppression of Activation of Receptor-bound Pro-urokinase* , 2004, Journal of Biological Chemistry.

[34]  Baljit Singh,et al.  Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. , 2003, Cancer research.

[35]  R. Schwartz,et al.  N-terminal Processing Is Essential for Release of Epithin, a Mouse Type II Membrane Serine Protease* , 2001, The Journal of Biological Chemistry.

[36]  J. Clements,et al.  Type II Transmembrane Serine Proteases , 2001, The Journal of Biological Chemistry.

[37]  C. Craik,et al.  Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Johnson,et al.  Molecular Cloning of cDNA for Matriptase, a Matrix-degrading Serine Protease with Trypsin-like Activity* , 1999, The Journal of Biological Chemistry.

[39]  R. Schwartz,et al.  Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains , 1999, Immunogenetics.

[40]  A. Levinson,et al.  Prevention of metastasis by inhibition of the urokinase receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Herrlich,et al.  Prevention of tumor metastasis formation by anti-variant CD44 , 1993, The Journal of experimental medicine.

[42]  S. Ha,et al.  Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma , 2013, Virchows Archiv.

[43]  T. Bugge,et al.  Matriptase: Potent Proteolysis on the Cell Surface , 2006, Molecular medicine.

[44]  B. Gullberg,et al.  Estimation of liver tumor volume using different formulas—An experimental study in rats , 2004, Journal of Cancer Research and Clinical Oncology.

[45]  R. Dickson,et al.  Deregulated activation of matriptase in breast cancer cells , 2004, Clinical & Experimental Metastasis.

[46]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..